ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ACAD Acadia Pharmaceuticals Inc

17.05
-0.03 (-0.18%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Acadia Pharmaceuticals Inc NASDAQ:ACAD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.03 -0.18% 17.05 16.90 31.00 17.5839 17.03 17.44 1,160,279 05:00:00

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

04/05/2021 2:00pm

Business Wire


Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Acadia Pharmaceuticals Charts.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences:

BofA Securities 2021 Health Care Conference Fireside Chat Presentation: Wednesday, May 12, 2021 at 2:45 p.m. Eastern Time

RBC Capital Markets Global Healthcare Conference Fireside Chat Presentation: Tuesday, May 18, 2021 at 3:05 p.m. Eastern Time

These conferences will be held virtually. Live webcasts of the presentations will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About Acadia Pharmaceuticals

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.

Media Contact: Acadia Pharmaceuticals Inc. Eric Endicott (858) 914-7161 media@acadia-pharm.com

Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA (858) 261-2771 ir@acadia-pharm.com

 

1 Year Acadia Pharmaceuticals Chart

1 Year Acadia Pharmaceuticals Chart

1 Month Acadia Pharmaceuticals Chart

1 Month Acadia Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock